[en] The von Willebrand factor (VWF) may be causally associated with coronary heart disease (CHD) or merely be a marker of endothelial damage. The G allele of the -1793 C/G promoter polymorphism in the VWF gene has been associated with higher plasma levels of VWF. To investigate whether VWF has a causal role in CHD, we designed a case-cohort study, including 352 subjects with CHD and a random cohort (n = 736), and prospectively examined the association of the -1793 C/G polymorphism with CHD in subjects with and without advanced atherosclerosis. All subjects were
Disciplines :
Genetics & genetic processes
Author, co-author :
van der Meer, Irene M.
Brouwers, Geert-Jan
BULK, Saskia ; Centre Hospitalier Universitaire de Liège - CHU > Génétique
Leebeek, Frank W. G.
van der Kuip, Deirdre A. M.
Hofman, Albert
Witteman, Jacqueline C. M.
Gomez Garcia, Encarnacion B.
Language :
English
Title :
Genetic variability of von Willebrand factor and risk of coronary heart disease: the Rotterdam Study.
Barlow, W.E. (1994) Robust variance estimation for the case-cohort design. Biometrics, 50, 1064-1072.
Barlow, W.E., Ichikawa, L., Rosner, D. & Izumi, S. (1999) Analysis of case-cohort designs. Journal of Clinical Epidemiology, 52, 1165-1172.
Brinkhous, K.M., Reddick, R.L., Read, M.S., Nichols, T.C., Bellinger, D.A. & Griggs, T.R. (1991) von Willebrand factor and animal models: contributions to gene therapy, thrombotic thrombocytopenic purpura, and coronary artery thrombosis. Mayo Clinic Proceedings, 66, 733-742.
Costa, M., Grant, P.J., Rice, G.I., Futers, T.S. & Medcalf, R.L. (2001) Human endothelial cell-derived nuclear proteins that recognise polymorphic DNA elements in the von Willebrand factor gene promoter include YY1. Thrombosis and Haemostasis, 86, 672-679.
Di Bitondo, R., Cameron, C.L., Daly, M.E., Croft, S.A., Steeds, R.P., Channer, K.S., Samani, N.J., Lillicrap, D. & Winship, P.R. (2001) The -1185 A/G and -1051 G/A dimorphisms in the von Willebrand factor gene promoter and risk of myocardial infarction. British Journal of Haematology, 115, 701-706.
Folsom, A.R., Wu, K.K., Rosamond, W.D., Sharrett, A.R. & Chambless, L.E. (1997) Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation, 96, 1102-1108.
Fowkes, F.G., Housley, E., Cawood, E.H., Macintyre, C.C., Ruckley, C.V. & Prescott, R.J. (1991) Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. International Journal of Epidemiology, 20, 384-392.
Fuster, V., Lie, J.T., Badimon, L., Rosemark, J.A., Badimon, J.J. & Bowie, E.J. (1985) Spontaneous and diet-induced coronary atherosclerosis in normal swine and swine with von Willebrand disease. Arteriosclerosis, 5, 67-73.
Harvey, P.J., Keightley, A.M., Lam, Y.M., Cameron, C. & Lillicrap, D. (2000) A single nucleotide polymorphism at nucleotide -1793 in the von Willebrand factor (VWF) regulatory region is associated with plasma VWF:Ag levels. British Journal of Haematology, 109, 349-353.
Hofman, A., Grobbee, D.E., de Jong, P.T. & van den Ouweland, F.A. (1991) Determinants of disease and disability in the elderly: the Rotterdam Elderly Study. European Journal of Epidemiology, 7, 403-422.
Jager, A., van Hinsbergh, V.W., Kostense, P.J., Emeis, J.J., Yudkin, J.S., Nijpels, G., Dekker, J.M., Heine, R.J., Bouter, L.M. & Stehouwer, C.D. (1999) von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: the Hoorn Study. Arteriosclerosis, Thrombosis, and Vascular Biology, 19, 3071-3078.
Jansson, J.-H., Nilsson, T.K. & Johnson, O. (1998) von Willebrand factor, tissue plasminogen activator, and dehydroepiandrosterone sulphate predict cardiovascular death in a 10 year follow up of survivors of acute myocardial infarction. Heart, 80, 334-337.
Keightley, A.M., Lam, Y.M., Brady, J.N., Cameron, C.L. & Lillicrap, D. (1999) Variation at the von Willebrand factor (vWF) gene locus is associated with plasma vWF:Ag levels: identification of three novel single nucleotide polymorphisms in the vWF gene promoter. Blood, 93, 4277-4283.
de Lange, M., Snieder, H., Ariens, R.A., Spector, T.D. & Grant, P.J. (2001) The genetics of haemostasis: a twin study. Lancet, 357, 101-105.
Lip, G.Y. & Blann, A.D. (1995) von Willebrand factor and its relevance to cardiovascular disorders. British Heart Journal, 74, 580-583.
Meijer, W.T., Hoes, A.W., Rutgers, D., Bots, M.L., Hofman, A. & Grobbee, D.E. (1998) Peripheral arterial disease in the elderly: the Rotterdam Study. Arteriosclerosis, Thrombosis, and Vascular Biology, 18, 185-192.
Methia, N., André, P., Denis, C.V., Economopoulos, M. & Wagner, D.D. (2001) Localized reduction of atherosclerosis in von Willebrand factor-deficient mice. Blood, 98, 1424-1428.
Ruggeri, Z.M. (2000) Old concepts and new developments in the study of platelet aggregation. Journal of Clinical Investigation, 105, 699-701.
Rumley, A., Lowe, G.D.O., Sweetnam, P.M., Yarnell, J.W.G. & Ford, R.P. (1999) Factor VIII, von Willebrand factor and the risk of major ischaemic heart disease in the Caerphilly Heart Study. British Journal of Haematology, 105, 110-116.
Saito, I., Folsom, A.R., Brancati, F.L., Duncan, B.B., Chambless, L.E. & McGovern, P.G. (2000) Nontraditional risk factors for coronary heart disease incidence among persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) Study. Annals of Internal Medicine, 133, 81-91.
Smith, F.B., Lee, A.J., Fowkes, F.G., Price, J.F., Rumley, A. & Lowe, G.D. (1997) Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study. Arteriosclerosis, Thrombosis, and Vascular Biology, 17, 3321-3325.
Souto, J.C., Almasy, L., Borrell, M., Gari, M., Martinez, E., Mateo, J., Stone, W.H., Blangero, J. & Fontcuberta, J. (2000) Genetic determinants of hemostasis phenotypes in Spanish families. Circulation, 101, 1546-1551.
Theilmeier, G., Michiels, C., Spaepen, E., Vreys, I., Collen, D., Vermylen, J. & Hoylaerts M.F. (2002) Endothelial von Willebrand factor recruits platelets to atherosclerosis-prone sites in response to hypercholesterolemia. Blood, 99, 4486-4493.
Thogersen, A.M., Jansson, J.H., Boman, K., Nilsson, T.K., Weinehall, L., Huhtasaari, F. & Hallmans, G. (1998) High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation, 98, 2241-2247.
Thompson, S.G., Kienast, J., Pyke, S.D., Haverkate, F. & van de Loo, J.C. (1995) Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. New England Journal of Medicine, 332, 635-641.
Whincup, P.H., Danesh, J., Walker, M., Lennon, L., Thomson, A., Appleby, P., Rumley, A. & Lowe, G.D. (2002) von Willebrand factor and coronary heart disease. Prospective study and meta-analysis. European Heart Journal, 23, 1764-1770.
World Health Organization (1992) International Statistical Classification of Diseases and Related Disorders. 10th revision, Geneva.
Zhang, Z.P., Blomback, M., Egberg, N., Falk, G. & Anvret, M. (1994) Characterization of the von Willebrand factor gene (VWF) in von Willebrand disease type III patients from 24 families of Swedish and Finnish origin. Genomics, 21, 188-193.
